Recomblnant Human Interferon a-2b Therapy, for Refractory Immyne Thrombocytopenic Purpura In Children

摘要

The study was designed to evaluate the effect of a-IFN, in patients with chronic immune thrombocytopenic purpura (ITP) who did not respond to conventional therapy; there were included 10 patients; 5 of them associated a chronic B or C hepatitis. The patients received IFN a-2b (3xl0~6 U/m~2/dose, sc, 3 times per week) for 6-18 months. We observed a good immediate response (increase of platelet count after 1 month of therapy) in 8 patients, followed by relapse after discontinuing IFN in 4 out of 7 responsive patients; 3 cases presented long-term remission; 2 out of 4 cases with chronic B hepatitis achieved seroconversion after 6-12 months of IFN.In conclusion, a-IFN may be an alternative therapy in patients who did not respond to standard therapy. It may be beneficial especially in patients who associate a chronic hepatitis, attempting to achieve a long-term remission and the seroconversion at the same time.